user-generated· valuation
AstraZeneca's pipeline premium erodes by 2027-06-30
Market overview
The company's historical pipeline premium is tied to consistent late-stage trial successes. The Wainua failure, combined with broader market scrutiny, could lead to a re-rating of AstraZeneca's valuation relative to peers, reducing its premium by at least 15%.
valuation prediction market
- Implied probability (Yes)
- 60%
- Closes
- 2027-06-30
More valuation markets
- Sambanova valuation exceeds $15B within 12 months of Series F close — 65% Yes
- Phia's valuation drops by 30% within 6 months due to scandal — 80% Yes
- SpaceX IPO valuation drops below $200B post-xAI dissolution — 60% Yes
- Anthropic's valuation will exceed $1 trillion by year-end 2026 — 72% Yes
- Lovable’s valuation exceeds $15B within 12 months of funding close — 60% Yes
- OpenAI to exceed $100B valuation by December 2026 — 72% Yes
- Ramp doubles valuation within 18 months of A* Fund III investment — 72% Yes
- Helsing valuation to exceed $25B within 12 months — 70% Yes
Loading…